MONOCLONAL ANTIBODY FOR CANCER TREATMENT (Q3133637): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item)
Property / budget
 
56,247.39 Euro
Amount56,247.39 Euro
UnitEuro
Property / budget: 56,247.39 Euro / rank
 
Normal rank
Property / co-financing rate
 
50.0 percent
Amount50.0 percent
Unitpercent
Property / co-financing rate: 50.0 percent / rank
 
Normal rank
Property / EU contribution
 
28,123.69 Euro
Amount28,123.69 Euro
UnitEuro
Property / EU contribution: 28,123.69 Euro / rank
 
Normal rank

Revision as of 15:06, 20 October 2021

Project Q3133637 in Spain
Language Label Description Also known as
English
MONOCLONAL ANTIBODY FOR CANCER TREATMENT
Project Q3133637 in Spain

    Statements

    contained in NUTS
    Madrid
    0 references
    country
    Spain
    0 references
    EU contribution
    28,123.69 Euro
    0 references
    budget
    56,247.39 Euro
    0 references
    co-financing rate
    50.0 percent
    0 references
    start time
    16 February 2015
    0 references
    end time
    14 December 2015
    0 references
    beneficiary name (string)
    ALTHIA HEALTH S.L.
    0 references
    beneficiary
    Q3133636
    0 references
    programme
    Madrid - ERDF
    0 references
    coordinate location

    40°25'0.12"N, 3°42'12.89"W
    0 references
    postal code
    28079
    0 references
    summary
    VALIDACIÓN DE UN ANTICUERPO MONOCLONAL PARA LA DETECCIÓN Y TRATAMIENTO DE CÉLULAS MADRE DEL CÁNCER EN TUMORES DE CEREBRO (Spanish)
    0 references
    VALIDATION OF A MONOCLONAL ANTIBODY FOR THE DETECTION AND TREATMENT OF CANCER MOTHER CELLS IN BRAIN TUMORS (English)
    0 references
    location (string)
    Madrid
    0 references

    Identifiers

    Spanish Kohesio ID
    DGEPF/01/21/002-17/18
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3133637&oldid=13025243"